drugset / Trial / NCT06122389

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

NCT06122389

Phase 3 Recruiting 130 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.

Timeline

Start
2024-02-05
Primary completion
2026-05
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR2554 Small molecule
Subject Tucidinostat Small molecule